MRK Merck & Company

$0.66 (0.84%)

MRK Stock Analysis Overview

What this means: InvestorsObserver gives Merck & Company (MRK) an overall rank of 50, which is below average. Merck & Company is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 50 means that 50% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full MRK report

Merck & Company (MRK) Analyst Forecast

Next 12 months ➝Current Price$78.7852-week High$92.6452-week Low$65.25MEAN$92.90+17.92%HIGH$107.00+35.82%LOW$88.00+11.70%
  • Last Price$78.78
  • Previous Close$78.12
  • Change $0.66
  • Open$78.57
  • Volume6,515,116
  • Avg. Volume (100-day)12,770,621
  • Market Capitalization$199B
  • Days Range $78.22 - $79.31
  • 52-week Range $65.25 - $92.64
  • Dividend Yield3.10%
  • Ex. Dividend Date06/12/2020
  • P-E19.9
  • EPS3.95
  • Earnings Date07/31/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • Avg. Analyst Rec.
  • Beta0.753
  • PEG Ratio2.16
  • Volatility0.29
  • Average True Range0.02
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.